Targets › TOPO2A
13 programs from 12 companies in 14 trials: 6 Phase 2, 6 Phase 3, 2 Phase 1; Oncology, Other, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on TOPO2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Modified FOLFIRINOX Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit | TOPO1, TOPO2A, MTHFR, TYMS | Phase 3 | Rectal Cancer | Dec 2026 |
| Sun Yat-sen University | mFOLFOXIRI Multi-drug chemotherapy regimen: oxaliplatin (platinum-based DNA crosslinker), irinotecan | TOPO1, TOPO2A, ERCC1 | Phase 3 | Colon Cancer Stage II | Dec 2026 |
| Children's Oncology Group | Bleomycin Sulfate Topoisomerase II inhibitor; DNA-damaging chemotherapy agent | TOPO2A | Phase 3 | Childhood Extracranial Germ Cell Tumor | Jun 2027 |
| Dominik Paul Modest | mFOLFOXIRI Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit | TOPO1, TOPO2A | Phase 3 | Colorectal Cancer | Nov 2027 |
| Azienda Ospedaliera Universitaria Integrata Verona | FOLFOX Combination of 5-fluorouracil, leucovorin, and oxaliplatin; topoisomerase II inhibitor and | TOPO2A | Phase 3 | Oligometastatic Gastric Adenocarcinoma | Sep 2028 |
| Sixth Affiliated Hospital, Sun Yat-sen University | Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication Topoisomerase II inhibitor (oxaliplatin, platinum-based chemotherapy) combined with antime | TOPO2A | Phase 2 | Chemotherapy Effect | Dec 2026 |
| Seoul National University Bundang Hospital | mFOLFOX/mFOLFIRI Combination of fluorouracil with oxaliplatin and irinotecan | TOPO1, TOPO2A | Phase 2 | Biliary Cancer Metastatic | Apr 2027 |
| Sun Yat-sen University | Teniposide Topoisomerase II inhibitor | TOPO2A | Phase 2 | Small-cell Lung Cancer | May 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | TEAM regimen High-dose chemotherapy conditioning regimen combining thiotepa (alkylating agent), etoposi | TOPO2A | Phase 2 | Lymphoma Patients With High-risk of Central Nervous System Relapse | Mar 2028 |
| Institut du Cancer de Montpellier - Val d'Aurelle | modified FOLFIRINOX regimen Combination chemotherapy: irinotecan (topoisomerase I inhibitor), oxaliplatin (platinum cr | TOPO1, TOPO2A, ERCC1 | Phase 2 | Locally Advanced Malignant Neoplasm | Sep 2029 |
| Hospital Universitario Doctor Peset | modified TPF Modified docetaxel-cisplatin-fluorouracil chemotherapy combination | TOPO2A, TOPO1 | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | – |
| GSK | Gepotidacin Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor | TOPO2A | Phase 1 | Urinary Tract Infections | May 2027 |
| University of Colorado, Denver | NALIRIFOX Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil (thymidyla | TOPO1, TOPO2A, TYMS | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Jul 2028 |
Oligometastatic Gastric Adenocarcinoma (2) Locally Advanced Head and Neck Squamous Cell Carcinoma (1) Rectal Cancer (1) Biliary Cancer Metastatic (1) Chemotherapy Effect (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Urinary Tract Infections (1) Lymphoma Patients With High-risk of Central Nervous System Relapse (1) Small-cell Lung Cancer (1) Colon Cancer Stage II (1) Childhood Extracranial Germ Cell Tumor (1) Colorectal Cancer (1)
small molecule (9), mixed (2)
Sun Yat-sen University (2) Hospital Universitario Doctor Peset (1) Assistance Publique - Hôpitaux de Paris (1) Seoul National University Bundang Hospital (1) Sixth Affiliated Hospital, Sun Yat-sen University (1) University of Colorado, Denver (1) GSK (1) Azienda Ospedaliera Universitaria Integrata Verona (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Children's Oncology Group (1) Dominik Paul Modest (1) Institut du Cancer de Montpellier - Val d'Aurelle (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.